AXA trimmed its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 29.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 397,431 shares of the biopharmaceutical company’s stock after selling 166,355 shares during the period. AXA’s holdings in Bristol-Myers Squibb were worth $22,145,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Staley Capital Advisers Inc. lifted its position in Bristol-Myers Squibb by 0.3% during the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock worth $379,000 after acquiring an additional 24 shares in the last quarter. British Columbia Investment Management Corp lifted its position in Bristol-Myers Squibb by 5.9% during the 1st quarter. British Columbia Investment Management Corp now owns 1,059,632 shares of the biopharmaceutical company’s stock worth $57,623,000 after acquiring an additional 59,193 shares in the last quarter. Kistler Tiffany Companies LLC lifted its position in Bristol-Myers Squibb by 11.3% during the 1st quarter. Kistler Tiffany Companies LLC now owns 11,674 shares of the biopharmaceutical company’s stock worth $635,000 after acquiring an additional 1,189 shares in the last quarter. Gabelli Funds LLC increased its holdings in Bristol-Myers Squibb by 4.9% during the 1st quarter. Gabelli Funds LLC now owns 839,887 shares of the biopharmaceutical company’s stock worth $45,673,000 after purchasing an additional 39,100 shares during the last quarter. Finally, RNC Capital Management LLC increased its holdings in Bristol-Myers Squibb by 3.7% during the 1st quarter. RNC Capital Management LLC now owns 11,179 shares of the biopharmaceutical company’s stock worth $608,000 after purchasing an additional 400 shares during the last quarter. 69.82% of the stock is currently owned by hedge funds and other institutional investors.
In other news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.23% of the company’s stock.
A number of equities research analysts have recently weighed in on the company. Barclays boosted their price target on Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. Jefferies Group downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target for the company. in a report on Monday, October 16th. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Leerink Swann upped their price objective on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Finally, Citigroup upped their price objective on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $64.93.
Bristol-Myers Squibb Company (NYSE:BMY) opened at $60.97 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The firm has a market capitalization of $101,508.14, a PE ratio of 20.95, a price-to-earnings-growth ratio of 2.35 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period in the previous year, the company earned $0.77 earnings per share. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. sell-side analysts anticipate that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thelincolnianonline.com/2017/12/07/bristol-myers-squibb-company-bmy-stake-decreased-by-axa-updated.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.